GQ Bio Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $30.6M

GQ Bio Therapeutics General Information

Description

Developer of a gene therapy vector platform (HCAd) designed to address challenges in the gene therapy field, including the transfer of large and multiple genes, efficient gene delivery, and large-scale manufacturability. The company's platform leverages AI to optimize the HCAd platform, including capsid engineering for tissue-specific gene therapy vectors, enabling the development of transformative treatments for chronic conditions such as osteoarthritis and intervertebral disc degeneration.

Contact Information

Formerly Known As
GeneQuine Biotherapeutics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Ballindamm 39
  • 20095 Hamburg
  • Germany
+49 040
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Parent Company
Corporate Office
  • Ballindamm 39
  • 20095 Hamburg
  • Germany
+49 040

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GQ Bio Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 27-Feb-2025 $30.6M Completed Generating Revenue
4. Grant 26-Jan-2021 Completed Generating Revenue
3. Later Stage VC (Series A) 26-Jan-2021 Completed Generating Revenue
2. Grant 15-Dec-2016 $100K $1.55M Completed Generating Revenue
1. Seed Round 12-Nov-2012 $1.55M $1.55M Completed Generating Revenue
To view GQ Bio Therapeutics’s complete valuation and funding history, request access »

GQ Bio Therapeutics Patents

GQ Bio Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024182549-A1 Compositions and methods for improved adenoviral- based gene therapy utilizing corticosteroid treatment Inactive 02-Mar-2023
US-20260174905-A1 Compositions and methods for improved adenoviral-based gene therapy utilizing corticosteroid treatment Pending 02-Mar-2023

GQ Bio Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GQ Bio Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
High-Tech Gründerfonds Venture Capital Minority
Innovationsstarter Accelerator/Incubator Minority
Investitionsbank des Landes Brandenburg Investment Bank
Merck Biopharma Corporation
Noshaq Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

GQ Bio Therapeutics FAQs

  • When was GQ Bio Therapeutics founded?

    GQ Bio Therapeutics was founded in 2012.

  • Where is GQ Bio Therapeutics headquartered?

    GQ Bio Therapeutics is headquartered in Hamburg, Germany.

  • What is the size of GQ Bio Therapeutics?

    GQ Bio Therapeutics has 20 total employees.

  • What industry is GQ Bio Therapeutics in?

    GQ Bio Therapeutics’s primary industry is Drug Discovery.

  • Is GQ Bio Therapeutics a private or public company?

    GQ Bio Therapeutics is a Private company.

  • What is the current valuation of GQ Bio Therapeutics?

    The current valuation of GQ Bio Therapeutics is .

  • What is GQ Bio Therapeutics’s current revenue?

    The current revenue for GQ Bio Therapeutics is .

  • How much funding has GQ Bio Therapeutics raised over time?

    GQ Bio Therapeutics has raised $11.5M.

  • Who are GQ Bio Therapeutics’s investors?

    High-Tech Gründerfonds, Innovationsstarter, Investitionsbank des Landes Brandenburg, Merck Biopharma, and Noshaq are 5 of 6 investors who have invested in GQ Bio Therapeutics.

  • When was GQ Bio Therapeutics acquired?

    GQ Bio Therapeutics was acquired on 27-Feb-2025.

  • Who acquired GQ Bio Therapeutics?

    GQ Bio Therapeutics was acquired by Pacira BioSciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process